BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會

TEACHER

Wei Wu

Session 8 – Healthcare Innovation Strategy

Date:28 July (Thursday)
Time:  12:20 – 13:50 (GMT+8)

Wei Wu

Principal, Venture Investments,
Johnson & Johnson Innovation – JJDC

Wei is a Principal of Johnson&Johnson Innovation- JJDC, the corporate venture group of J&J. She initiates and manages equity investments in biopharma, medical device, and consumer health, to drive innovation and fuel new and sustainable businesses. Prior to joining JJDC, Wei was a Senior Associate at Illumina Ventures with a focus on genomics-enabled precision medicine including therapeutics, diagnostics, and life science tools. Prior to that, she was the Director of Healthcare Investment and Business Development of BOE Ventures where she focused on VC fund investment, direct investment, and business development opportunities at the intersection of technology and life sciences. Before becoming an investor, Wei was a R&D project lead at NuGEN Technologies (later acquired to become TECAN Genomics). Wei received her Ph.D. from UCLA in Biological Chemistry and completed her postdoctoral research in the Department of Pathology at Stanford University. She received a Bachelor of Science in Biological Sciences from Peking University, China. She published in top-tier journals including Cell, Nature, neuron, Nature Review Genetics and served as a reviewer and editorial board member for numerous international biomedical journals.
 

Speech title & Synopsis

Integrating Global Innovation Networks

Johnson&Johnson Innovation-JJDC is the corporate venture arm of Johnson&Johnson. Established in 1973, we are one of the healthcare corporate ventures with the longest history. We aspire to drive innovation and fuel new and sustainable businesses through equity investment. In this talk, I will provide an overview of the investment thesis and deal types that Johnson&Johnson Innovation-JJDC deploy when working with our external partners.